Data contain private patient information and are unsuitable for public deposition. Patient and imaging data are available upon request from the Knight Alzheimer\'s Disease Research Center (ADRC) (<http://knightadrc.wustl.edu/>) with approval from the ADRC executive committee. The guidelines for data requests can be found at (<http://knightadrc.wustl.edu/Research/PDFs/Guidelines2013.pdf>). Contact the executive associate director, Dr. Krista Moulder (<moulderk@abraxas.wustl.edu>) for details. For imaging data, contact the ADRC Neuroimaging Core leader, Dr. Tammie Benzinger (<benzingert@mir.wustl.edu>).

Introduction {#sec001}
============

Alzheimer's disease (AD) is the most common form of dementia \[[@pone.0122920.ref001]\]. Its prevalence is expected to increase dramatically worldwide within the next 50 years as aging prevails across the globe \[[@pone.0122920.ref002]\]. The future success of disease-modifying therapies will depend on accurate early diagnosis of the disease before any clinical symptoms occur \[[@pone.0122920.ref003]\]. Although the underlying disease mechanism is still unclear, AD is characterized by two pathological hallmarks: amyloid plaques, and neurofibrillary tangles \[[@pone.0122920.ref001]\]. These pathological changes begin at least 10 to 20 years before clinical symptoms appear \[[@pone.0122920.ref001],[@pone.0122920.ref004]--[@pone.0122920.ref006]\]. Currently, there are no disease-modifying treatments available \[[@pone.0122920.ref007]\], however, there is a growing consensus that effective treatment of AD may require early intervention before the onset of clinical symptoms, and well validated surrogate biomarkers are needed for the future treatment development and the design of therapy trials \[[@pone.0122920.ref008],[@pone.0122920.ref009]\]. Among the various biomarkers identified, positron emission tomography (PET) imaging of the beta-amyloid (Aβ) plaques with tracers such as \[^11^C\]PiB \[[@pone.0122920.ref010]\], \[^18^F\]florbetapir \[[@pone.0122920.ref011]\], \[^18^F\]florbetaben \[[@pone.0122920.ref012]\] and \[^18^F\]flutemetamol\[[@pone.0122920.ref013]\], is the earliest indicator of AD pathology because they are capable of *in vivo* measurement of the amount of amyloid plaques in the brain. It is critical to quantify Aβ burden accurately and robustly to further our understanding of disease mechanisms, to develop early diagnostic techniques, and to identify suitable surrogate indicators for treatment monitoring and efficacy evaluation.

With amyloid PET imaging, the amount of amyloid plaque in the brain is commonly assessed based on some variant of a two-tissue compartment kinetic model \[[@pone.0122920.ref014],[@pone.0122920.ref015]\]. In this model ([Fig 1](#pone.0122920.g001){ref-type="fig"}), the PET tracer is assumed to present in three different forms, in the vasculature (vasculature compartment), in the brain tissue as free or nonspecifically-bound tracer (nondisplaceable compartment), and specifically bound tracer (specific compartment) \[[@pone.0122920.ref016]\]. The concentration of the PET tracer in these compartments are governed by a set of differential equations \[[@pone.0122920.ref017]\]: $$\frac{dC_{ND}}{dt} = K_{1}C_{P} - (k_{2} + k_{3})C_{ND} + k_{4}C_{S}$$ $$\frac{dC_{S}}{dt} = k_{3}C_{ND} - k_{4}C_{S}$$ Where *C* ~*P*~ is the tracer concentration within the vasculature compartment, which is also commonly referred to as the arterial input function (AIF); *C* ~*ND*~ is the tracer concentration within the nondisplaceable compartment; *Cs* is the tracer concentration within the specific compartment; and the kinetic rate constants *K* ~*1*~ *-k* ~*4*~ describes the rate of tracer transfer among compartments ([Fig 1](#pone.0122920.g001){ref-type="fig"}). With PET, the tracer concentration in the tissue as a function of time (*C* ~*T*~) can be directly measured. If the plasma concentration of the tracer (*C* ~*P*~) is also known, then the kinetic rate constants *K* ~*1*~ *-k* ~*4*~ can be determined via kinetic modeling \[[@pone.0122920.ref017]\]. The kinetic modeling is commonly formulated as a non-linear least square fit procedure that minimizes the difference between model-based *C* ~*T*~ (Eqs [3](#pone.0122920.e003){ref-type="disp-formula"} and [4](#pone.0122920.e004){ref-type="disp-formula"}) and PET measured *C* ~*T*~ \[[@pone.0122920.ref017],[@pone.0122920.ref018]\].
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![Illustration of two-tissue compartment model.\
Two of the compartments are located within the tissue: the nondisplaceable compartment containing free plus nonspecifically bound tracer; and the specific compartment containing specifically bound tracer. (BBB: blood-brain barrier; *C* ~*P*~, tracer concentration within the vasculature compartment; *C* ~*ND*~, tracer concentration within the nondisplaceable compartment; *Cs*, tracer concentration within the specific compartment; *C* ~*T*~, tracer concentration in the tissue including both the nondisplaceable compartment and the specific compartment; *K* ~*1*~, the influx rate constant of tracer from the vasculature compartment to the tissue; *k* ~*2*~, the washout rate constant of tracer from the tissue to the vasculature; *k* ~*3*~, the rate constant for tracer transfer from the nondisplaceable compartment to the specific compartment; *k* ~*4*~, the rate constant for tracer transfer from specific compartment to the nondisplaceable compartment.)](pone.0122920.g001){#pone.0122920.g001}

After determination of kinetic rate constants, the binding potential (*BP* ~*ND*~ = *k* ~*3*~ */k* ~*4*~) can be calculated \[[@pone.0122920.ref016],[@pone.0122920.ref017]\], which is of specific interest in amyloid PET imaging because it is proportional to regional amyloid plaque density in the brain \[[@pone.0122920.ref016],[@pone.0122920.ref019]\]. As we mentioned earlier, the kinetic modeling process requires the knowledge of *C* ~*P*~. The conventional method to obtain AIF is via an invasive arterial sampling procedure \[[@pone.0122920.ref014],[@pone.0122920.ref015]\]. Aside from the invasive nature, this method is also noisy and technically challenging \[[@pone.0122920.ref020],[@pone.0122920.ref021]\]. To avoid arterial sampling, the current standard amyloid imaging analysis uses a reference region based approach \[[@pone.0122920.ref014],[@pone.0122920.ref019]\], where, a reference region, normally cerebellar cortex, is assumed to be amyloid free and have the same tracer influx to washout ratio as the target regions of interest. Regional binding potential can be calculated by comparing region of interest PET signal against the reference region signal based on some variation of the standard two-tissue compartment model \[[@pone.0122920.ref014],[@pone.0122920.ref019]\]. In one implementation of the reference region based approach, a Logan graphical analysis model with reference region ([Eq 5](#pone.0122920.e005){ref-type="disp-formula"}) \[[@pone.0122920.ref022],[@pone.0122920.ref023]\] is derived based on the original two-tissue compartment model. $$\frac{\int\limits_{0}^{T}{C_{T}(t)dt}}{C_{T}(T)} = DVR\left( \frac{\int\limits_{0}^{T}{C_{R}(t)dt + \frac{C_{R}(T)}{k_{2}^{'}}}}{C_{T}(T)} \right) + Int$$ Where, *C* ~*R*~ is the reference region tracer concentration; *k* ~*2*~ *'* is the reference region washout rate constant, and DVR is the distribution volume ratio and it is related to the rate constants and binding potential as described in [Eq 6](#pone.0122920.e006){ref-type="disp-formula"}, under the condition that *K* ~*1*~ */k* ~*2*~ = *K* ~*1*~ *'*/*k* ~*2*~ *'* (*K* ~*1*~ *'* is the reference region influx rate constant) with no specific binding in the reference region.
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Because of the fact that DVR is directly related to binding potential, it is also commonly used as the outcome parameter in amyloid PET imaging quantification \[[@pone.0122920.ref014],[@pone.0122920.ref015]\]. Another commonly used reference region based imaging quantification measurement is the standardized uptake value ratio (SUVR) \[[@pone.0122920.ref024],[@pone.0122920.ref025]\], which is simply the ratio of target region image intensity to the reference region intensity. This measurement approximates DVR with the benefits of requiring shorter scan time while introducing systematic biases \[[@pone.0122920.ref014],[@pone.0122920.ref026]\]. While a cerebellar reference may be valid for many occasions, several conditions may make the assumption problematic \[[@pone.0122920.ref027]\], including prion disease \[[@pone.0122920.ref028],[@pone.0122920.ref029]\] and familial AD \[[@pone.0122920.ref030]\], where amyloid deposition also occurs in the cerebellar cortex, leading to the invalidity of the assumptions of the reference region based technique. The observation of amyloid deposition in the cerebellar cortex of familial AD cases \[[@pone.0122920.ref031],[@pone.0122920.ref032]\] prompted identification and validation of pons as an alternative reference region \[[@pone.0122920.ref024]\]. For the same reason, in a recent study from the Dominantly Inherited Alzheimer Network (DIAN), brain stem was used as the reference for quantification \[[@pone.0122920.ref004]\]. Nevertheless, in an earlier study that validated different amyloid imaging quantification techniques, an increase, although non-significant, in tracer uptake for pons was observed in the AD group \[[@pone.0122920.ref015]\]; in addition, in the study which validated pons as a reference region, an elevation in PiB retention in pons was observed in an early onset AD patient albeit at a smaller level than cerebellar cortex \[[@pone.0122920.ref024]\]. Therefore we cannot rule out the possibility of specific tracer uptake in the pons in patients either. Moreover, any physiological/pathological changes in the region used as reference unrelated to amyloid deposition, such as stroke, infarct, or hemorrhage, will confound the amyloid imaging quantification by altering the delivery, transport and nonspecific binding of the tracer, i.e. invalidates the assumption that *K* ~*1*~ */k* ~*2*~ = *K* ~*1*~ *'*/*k* ~*2*~ *'*.

Given the fact that reference region based techniques can be problematic in some patient populations, we decided to investigate the feasibility of quantitative analysis techniques using full kinetic modeling with AIF. As previously mentioned, the amount of amyloid deposited in the brain can be directly estimated using kinetic modeling with the knowledge of AIF without a reference region \[[@pone.0122920.ref016],[@pone.0122920.ref017]\]. In fact, kinetic modeling with arterial sampling derived AIF was the gold standard technique against which the reference region based approach was validated \[[@pone.0122920.ref014],[@pone.0122920.ref015],[@pone.0122920.ref024]\]. However, conventional arterial sampling technique is invasive and challenging \[[@pone.0122920.ref020],[@pone.0122920.ref021]\]. On the other hand, a number of groups have investigated the possibility of deriving AIF from imaging data without the need of arterial sampling \[[@pone.0122920.ref033]--[@pone.0122920.ref035]\]. Although this is an approach that has been studied for many years \[[@pone.0122920.ref034],[@pone.0122920.ref036]--[@pone.0122920.ref040]\], a recent evaluation study of many of these approaches suggested none of them could reliably estimate the AIF without arterial samples \[[@pone.0122920.ref033]\]. We believe the key reason for the failure of these methods is the fact that they are solely dependent upon the PET data itself which does not have the spatial resolution needed to identify pure vascular signal \[[@pone.0122920.ref033],[@pone.0122920.ref038],[@pone.0122920.ref041]--[@pone.0122920.ref043]\]. Recently, we developed an imaging-derived AIF (IDAIF) technique that combines high resolution anatomical data with PET data, and demonstrated its feasibility and robustness in the context of ^15^O-water PET studies \[[@pone.0122920.ref044]\]. Therefore, the current goal is to adapt our IDAIF based technique for amyloid imaging to determine whether quantification can be achieved without the need of a reference region or the invasive arterial sampling procedure. We will use the IDAIF technique to quantify amyloid deposition in a cohort of normal elderly and very mild AD patients, and compare the results with conventional reference region based technique.

Methods {#sec002}
=======

I. Participants {#sec003}
---------------

A total of 21 subjects were included in this study. They were all part of the Knight Alzheimer's Disease Research Center (ADRC) research participants enrolled in longitudinal studies of memory and aging. Using a mean cortical binding potential (MCBP) cutoff of 0.18 as measured by PiB PET imaging \[[@pone.0122920.ref019]\], 13 were considered PiB- (MCBP\<0.18), the rest (N = 8) were PiB+ (MCBP\>0.18). Four out of the eight participants in the PiB+ group had a CDR score of 0.5 or greater. Demographic details are provided in [Table 1](#pone.0122920.t001){ref-type="table"}. It should be pointed out that we specifically selected this population, where reference region based technique is considered valid \[[@pone.0122920.ref014],[@pone.0122920.ref024]\], so that the proposed IDAIF technique can be tested against. In a future study, we will further evaluate the proposed technique in populations where the reference region based approach is problematic.

10.1371/journal.pone.0122920.t001

###### Demographics for this study.

![](pone.0122920.t001){#pone.0122920.t001g}

  Cohort                     PIB-        PIB+
  -------------------------- ----------- -----------
  **N**                      13          8
  **Age (SD) years**         72.5(8.6)   75.4(6.6)
  **Education (SD) years**   15.4(2.1)   16.7(3.5)
  **Male (%)**               6(46.2)     6(75.0)
  **CDR\>0 (%)**             0(0.0)      4(50)
  **APOE4+ (%)**             5(38.5)     5(62.5)

### I.1 Ethics Statement {#sec004}

All assessment and imaging procedures were approved by Washington University's Human Research Protection Office, and written informed consent was obtained from all individuals or their care-givers.

II. Imaging {#sec005}
-----------

PET imaging for amyloid deposition was performed using the radiotracer PiB. Preparation of PiB was carried out based on existing protocol \[[@pone.0122920.ref045]\]. Dynamic PET imaging was conducted with a Biograph 40 PET/CT scanner (Siemens Medical Solutions USA, Inc.) in three-dimensional mode after intravenous administration of approximately 12mCi of PiB. The images were reconstructed on a 128 x 128 x 109 matrix (2.32 x 2.32 x 2.03 mm) using filtered back-projection. Typical dynamic scans had 12 x 10-second frames, 3 x 1-minute frames, and 11 x 5-minute frames. Anatomical MRI images were acquired with T1-weighted magnetization-prepared rapid gradient echo (MPRAGE) sequence (TE = 3.16 msec, TI = 1000 msec, TR = 2400 msec) using a Siemens Trio 3T scanner with1 mm isotropic voxels. Time-of-flight (TOF) MR angiography (MRA) data was acquired (TE = 3.59 msec, TR = 23.0 msec, Flip = 18°) with 0.6 mm isotropic voxels on the same scanner.

III. Image Analysis {#sec006}
-------------------

The standard image analysis technique has been discussed previously \[[@pone.0122920.ref046]\] and a PET Unified Pipeline (PUP) (<https://github.com/ysu001/PUP>) has been developed by our group to facilitate automated PET data analysis. In summary, before PET data analysis using PUP, automatic brain segmentation and parcellation of the MPRAGE data was performed using FreeSurfer v5.1 (Martinos Center for Biomedical Imaging, Charlestown, Massachusetts, USA) for each participant. In all datasets, visual inspection of the automated segmentation results was performed for quality assurance purposes, and correction was done when necessary according to the FreeSurfer manual. Using PUP, raw PET images were normalized to achieve a common spatial resolution of 8mm to minimize scanner differences according to an established method \[[@pone.0122920.ref047]\] as a part of our standard PET processing procedure. PET to MR and TOF-MRA to MR registration were performed using a vector-gradient algorithm (VGM) \[[@pone.0122920.ref048]\]. Atlas registration (12-parameter affine) was performed via the MPRAGE against a standard atlas template. Inter-frame motion correction for the dynamic PET images was performed using standard image registration techniques \[[@pone.0122920.ref049]\]. Regional time-activity curves for each ROI were extracted by resampling the PET image to the MR space. Regional distribution volume ratio (*DVR* ~*REF*~) was estimated using Logan graphical analysis with cerebellar cortex as the reference \[[@pone.0122920.ref022]\]. The linear fit in the Logan analysis was performed based on PET data between 30 to 60 minutes. A mean cortical *DVR* (*MCDVR*) was also calculated based on a selected set of cortical regions \[[@pone.0122920.ref046]\]. The washout rate constant (*k* ~*2*~ *'*) of the reference region (cerebellar cortex) was set to 0.16/minute. It has previously been shown that varying *k* ~*2*~ *'* over a 10-fold range (0.05 to 0.5/minute) has minimal impact on the *DVR* values \[[@pone.0122920.ref019]\].

IV. IDAIF Method {#sec007}
----------------

Similar to our previous work \[[@pone.0122920.ref044]\], a modified adaptive segmentation algorithm \[[@pone.0122920.ref050]\] is used to automatically segment the MRA images to identify arteries ([Fig 2](#pone.0122920.g002){ref-type="fig"}). The arterial mask is smoothed to PET resolution (8mm FWHM) and transferred to the MPRAGE space. A threshold is automatically determined to obtain a 16 cc volume after thresholding the blurred arterial mask within a rectangular box predefined in the atlas space centered at the petrous portion of the internal carotid artery. This thresholded mask is used as the arterial ROI (ROIa) for AIF estimation ([Fig 2](#pone.0122920.g002){ref-type="fig"}). A lower threshold is also automatically determined to obtain a 100 cc volume (ROIb) after thresholding the arterial mask, and the subtraction image of ROIa from ROIb was used as the background mask (BG) ([Fig 2](#pone.0122920.g002){ref-type="fig"}). The TAC curve for ROIa is assumed to follow the model below:
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![Three dimensional rendering of time-of-flight MRA (A), segmented arterial tree (B), the arterial region-of-interest (ROIa) (C), and one example slice of the arterial ROI (ROIa) and the background region-of-interest (BG) (D).\
Example slice of coregistered MRI (E), MRA (F), PET(G), and ROIa (H).](pone.0122920.g002){#pone.0122920.g002}

The variables *r* and *s* in [Eq 7](#pone.0122920.e007){ref-type="disp-formula"} are the recovery and spill over coefficients respectively to account for the limited spatial resolution of PET; *C* ~*B*~ is the whole blood activity concentration.

The AIF is derived based on fitting a kinetic model to the TAC of one large brain tissue ROI (*C* ~*t*~), i.e. in our implementation the cerebellar cortex was used because it is the largest ROI generated by FreeSurfer segmentation although any large brain region can be used instead. In this study, we combined two one-tissue compartmental models \[[@pone.0122920.ref016],[@pone.0122920.ref017]\] to approximate the tracer kinetics. The first one-tissue compartmental model ([Eq 8](#pone.0122920.e008){ref-type="disp-formula"}) approximates the early kinetic behavior, i.e. before *C* ~*t*~ peaks, $$\frac{dC_{t}}{dt} = K_{1}C_{P} - k_{2}C_{t}$$ Where, *C* ~*t*~ is tissue time activity curve in the selected ROI; *C* ~*P*~ is the AIF; *K* ~*1*~ and *k* ~*2*~ are the influx and washout rate constant for the one-tissue compartment model. A second one-tissue compartmental model ([Eq 9](#pone.0122920.e009){ref-type="disp-formula"}) approximates the two-tissue compartment kinetic behavior using a one-tissue compartment model for late time points, i.e. after 40 minutes. $$\frac{dC_{t}}{dt} = K_{1}C_{P} - k_{2a}C_{t}$$ where, k~2a~ = k~2~/(1+k~3~/k~4~) \[[@pone.0122920.ref017]\]. This second one-tissue compartmental model has been proposed and used widely in the simplified reference tissue model \[[@pone.0122920.ref051]\]. In this model, *k* ~*2a*~ is the effective washout rate constant; *k* ~*2*~ is the washout rate constant for the two-tissue compartment model, and *k* ~*3*~ and *k* ~*4*~ are the binding rate constants. For time in between, the kinetics is described by a linear mixture of the two one-tissue compartmental models. For a given set of *C* ~*t*~, *K* ~*1*~, *k* ~*2*~, and *k* ~*2a*~, the AIF, i.e. *C* ~*P*~, can be calculated as the following: $$\left\{ \begin{matrix}
{C_{P} = \frac{1}{K_{1}}\frac{dC_{t}}{dt} + \frac{k_{2}}{K_{1}}C_{t},\mspace{27mu} t < t_{peak}} \\
{C_{P} = \frac{1}{K_{1}}\frac{dC_{t}}{dt} + \frac{k_{2a}}{K_{1}}C_{t},\mspace{27mu} t > 40\,\text{min}} \\
{C_{P} = w_{1}\left( {\frac{1}{K_{1}}\frac{dC_{t}}{dt} + \frac{k_{2}}{K_{1}}C_{t}} \right) + w_{2}\left( {\frac{1}{K_{1}}\frac{dC_{t}}{dt} + \frac{k_{2a}}{K_{1}}C_{t}} \right),\mspace{27mu} t_{peak} \leq t \leq 40\,\text{min}} \\
\end{matrix} \right.$$ where, *w* ~*1*~ and *w* ~*2*~ are weighting factors, with *w* ~*1*~ linearly decreases from 1 to 0 and *w* ~*2*~ increases from 0 to 1.

To estimate AIF the following cost function is minimized by in a nonlinear least square fashion: $$Q(K_{1},k_{2},K_{2a},s) = {\sum\limits_{i = 1}^{F}\left\lbrack {C_{ROIa}^{PET}(i) - C_{ROIa}^{MOD}(i)} \right\rbrack^{2}}$$ where, *i* is the frame index, *F* is the total number of frames, $C_{ROIa}^{PET}$ refers to PET measured TAC for ROIa, and $C_{ROIa}^{MOD}$ refers to model estimated TAC for the arterial ROI (ROIa) as modeled according to [Eq 7](#pone.0122920.e007){ref-type="disp-formula"}. The recovery coefficient *r* is determined based on the arterial ROI using a 8mm FWHM Gaussian as the point spread function; *s* is estimated as one of the model parameters in [Eq 11](#pone.0122920.e011){ref-type="disp-formula"}; *C* ~*B*~ is estimated based on the AIF (*C* ~*P*~) by applying population average parent compound ratio \[[@pone.0122920.ref014]\]. With two PET derived time activity curves from coregistered PET and MR ([Fig 2](#pone.0122920.g002){ref-type="fig"}), i.e. $C_{ROIa}^{PET}$ and *Ct*, an optimal set of parameters (*K* ~*1*~, *k* ~*2*~, *k* ~*2a*~, and *s*) are determined that minimizes the cost *Q*, then AIF is calculated according to [Eq 10](#pone.0122920.e010){ref-type="disp-formula"}.

V. Quantification using IDAIF {#sec008}
-----------------------------

With AIF determined using the method described above, for each FreeSurfer region, regional distribution volume (*V* ~*T*~) is calculated using Logan analysis with arterial input \[[@pone.0122920.ref052]\].
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Full kinetic modeling is then performed using the IDAIF according to the two-tissue compartment model (Eqs [1](#pone.0122920.e001){ref-type="disp-formula"}--[4](#pone.0122920.e004){ref-type="disp-formula"}) \[[@pone.0122920.ref017]\]. In this work, independent model parameters *K* ~*1*~, *K* ~*1*~ */k* ~*2*~, and *k* ~*3*~ were directly estimated using nonlinear least square fit; *V* ~*T*~ is kept fixed using the value obtained from Logan graphical analysis with arterial input. Distribution volume ratio *DVR* ~*kinetic*~ was then calculated as *V* ~*T*~ */(K* ~*1*~ */k* ~*2*~ *)*.

VI. Evaluation of the IDAIF technique {#sec009}
-------------------------------------

To demonstrate the validity of the IDAIF based technique for amyloid PET imaging quantification, we analyzed the quantification results in the following three aspects: 1) we compared the estimated cerebellar cortex V~T~ against literature reported values; 2) we examined whether DVR calculated using the IDAIF technique was able to differentiate the PiB+ group from PiB- group using two-tailed Welch's t-test; 3) we compared the estimated DVR using the IDAIF technique against reference region based DVR using both Pearson's correlation (r) and intraclass correlation (ICC) as the descriptive statistical parameters.

Results {#sec010}
=======

An estimated AIF using the image based technique was demonstrated in [Fig 3A](#pone.0122920.g003){ref-type="fig"}, and an excellent model fitting was achieved as shown in [Fig 3B](#pone.0122920.g003){ref-type="fig"}. Using IDAIF, estimated regional distribution volume (*V* ~*T*~) was summarized in [Table 2](#pone.0122920.t002){ref-type="table"}. The *V* ~*T*~ for cerebellar cortex for the PiB- group was 3.20±0.47 with a 14.8% coefficient of variation. The mean value was in agreement with the reported *V* ~*T*~ in control populations \[[@pone.0122920.ref015]\]. The variability of cerebellar *V* ~*T*~ was also in line with previous studies \[[@pone.0122920.ref014],[@pone.0122920.ref015],[@pone.0122920.ref024]\]. The distribution of outcome measurements for the PiB- (N = 13) and PiB+ (N = 8) groups were illustrated in [Fig 4](#pone.0122920.g004){ref-type="fig"}. All the outcome measurements, i.e. the DVRs, were significantly different (p\<0.01) between the two groups for caudate, precuneus, gyrus rectus, lateral temporal, prefrontal, and mean cortical regions using two-tailed Welch's t-test. Also, as expected, the brain stem and cerebellar cortex do not show differences between the two groups. The estimated regional *DVR* by full kinetic modeling using IDAIF (*DVR* ~*kinetic*~) was in excellent agreement (r = 0.8995, ICC = 0.8342) with the reference region based approach (*DVR* ~*REF*~) ([Fig 5](#pone.0122920.g005){ref-type="fig"}). The largest discrepancies between *DVR* ~*kinetic*~ (1.10) and *DVR* ~*REF*~ (1.35) was 18% which was primarily due to the differences in tracer delivery and nonspecific binding between the target region (*K* ~*1*~ */k* ~*2*~ = 3.07 for cortical mean) and reference region (*V* ~*T*~ = 2.51 for cerebellar cortex).

![Example cerebellar cortex TAC, arterial ROI TAC and estimated AIF (A); comparison of PET measured TAC and model estimated TAC for the arterial ROI (B).](pone.0122920.g003){#pone.0122920.g003}

![Comparison of different outcome measurements between the PiB- (open downward triangles) and the PiB+ group (solid upward triangles) for selected regions.\
CER: cerebellar cortex; BS: brain stem; CAU: caudate; PREC: precuneus; GR: gyrus rectus; TEMP: lateral temporal; PREF: prefrontal; MC: mean cortical. *V* ~*T*~: distribution volume; *DVR* ~*REF*~: target-region-to-cerebellum distribution volume ratio estimated using Logan graphical analysis with reference region (cerebellar cortex); *DVR* ~*kinetic*~: *V* ~*T*~ */(K1/k2)* estimated using full kinetic modeling with IDAIF.](pone.0122920.g004){#pone.0122920.g004}

![Comparisons of mean cortical DVR estimated with IDAIF and reference tissue model.](pone.0122920.g005){#pone.0122920.g005}

10.1371/journal.pone.0122920.t002

###### Regional *V* ~*T*~, regional *DVR* estimated using Logan analysis with cerebellar reference (*DVR* ~*REF*~), and regional *DVR* estimated with full kinetic model (*DVR* ~*kinetic*~).

![](pone.0122920.t002){#pone.0122920.t002g}

  Region                  logan V~*T*~                                                                                                      DVR~*REF*~                                                                                                       DVR~*kinetic*~                                          
  ----------------------- -------------------------------------------------------- -------------------------------------------------------- ------------------------------------------------------- -------------------------------------------------------- ------------------------------------------------------- --------------------------------------------------------
  **Cerebellar Cortex**   3.20±0.47 (14.8%)                                        3.21±0.61 (19.0%)                                        1                                                       1                                                        1.09±0.04 (3.7%)                                        1.10±0.03 (3.0%)
  **Brain Stem**          4.41±0.70 (15.9%)                                        4.49±0.84 (18.8%)                                        1.37±0.06 (4.3%)                                        1.40±0.10 (6.9%)                                         1.30±0.11 (8.4%)                                        1.30±0.18 (14.2%)
  **Precuneus**           3.60±0.51 (14.2%)[\*](#t002fn002){ref-type="table-fn"}   5.50±1.86 (33.8%)[\*](#t002fn002){ref-type="table-fn"}   1.12±0.05 (4.2%)[\*](#t002fn002){ref-type="table-fn"}   1.66±0.28 (17.0%)[\*](#t002fn002){ref-type="table-fn"}   1.18±0.05 (4.6%)[\*](#t002fn002){ref-type="table-fn"}   1.54±0.23 (15.2%)[\*](#t002fn002){ref-type="table-fn"}
  **Temporal**            3.19±0.51 (15.9%)                                        4.46±1.60 (35.8%)                                        0.99±0.04 (4.3%)[\*](#t002fn002){ref-type="table-fn"}   1.35±0.26 (19.1%)[\*](#t002fn002){ref-type="table-fn"}   1.08±0.04 (3.6%)[\*](#t002fn002){ref-type="table-fn"}   1.33±0.19 (14.5%)[\*](#t002fn002){ref-type="table-fn"}
  **Prefrontal**          3.15±0.51 (14.7%)[\*](#t002fn002){ref-type="table-fn"}   4.93±1.51 (30.5%)[\*](#t002fn002){ref-type="table-fn"}   0.98±0.04 (4.6%)[\*](#t002fn002){ref-type="table-fn"}   1.50±0.21 (13.8%)[\*](#t002fn002){ref-type="table-fn"}   1.18±0.06 (4.9%)[\*](#t002fn002){ref-type="table-fn"}   1.56±0.17 (10.6%)[\*](#t002fn002){ref-type="table-fn"}
  **Gyrus Recus**         3.38±0.59 (17.3%)[\*](#t002fn002){ref-type="table-fn"}   5.12±1.66 (32.5%)[\*](#t002fn002){ref-type="table-fn"}   1.05±0.05 (5.1%)[\*](#t002fn002){ref-type="table-fn"}   1.55±0.25 (15.8%)[\*](#t002fn002){ref-type="table-fn"}   1.15±0.05 (4.0%)[\*](#t002fn002){ref-type="table-fn"}   1.48±0.18 (11.9%)[\*](#t002fn002){ref-type="table-fn"}
  **Caudate**             3.23±0.50 (15.6%)[\*](#t002fn002){ref-type="table-fn"}   4.25±1.17 (27.6%)[\*](#t002fn002){ref-type="table-fn"}   1.00±0.05 (5.0%)[\*](#t002fn002){ref-type="table-fn"}   1.30±0.16 (12.0%)[\*](#t002fn002){ref-type="table-fn"}   1.28±0.06 (4.8%)[\*](#t002fn002){ref-type="table-fn"}   1.51±0.18 (11.9%)[\*](#t002fn002){ref-type="table-fn"}
  **MC**                  3.33±0.52 (15.7%)[\*](#t002fn002){ref-type="table-fn"}   5.00±1.65 (32.9%)[\*](#t002fn002){ref-type="table-fn"}   1.03±0.04 (3.8%)[\*](#t002fn002){ref-type="table-fn"}   1.51±0.24 (15.9%)[\*](#t002fn002){ref-type="table-fn"}   1.15±0.05 (4.0%)[\*](#t002fn002){ref-type="table-fn"}   1.48±0.19 (12.5%)[\*](#t002fn002){ref-type="table-fn"}

MC: the regions that went into the calculation of MCBP using a FreeSurfer based approach \[[@pone.0122920.ref046]\].

\*Significantly different between PiB- and PiB+ group (p\<0.05).

Discussion {#sec011}
==========

We developed and implemented a technique that estimates arterial input function from the PET images with the help of coregistered TOF-MRA data. We evaluated this technique in the context of amyloid PET imaging quantification and found excellent agreement between the AIF and reference region based quantification. The evaluation was done in a cohort of normal elderly and patients with very mild AD dementia where cerebellar cortex was a good reference region with no specific uptakes as has been shown in previous studies \[[@pone.0122920.ref014],[@pone.0122920.ref015]\]. Given the linearized model for Logan graphical analysis with arterial input ([Eq 12](#pone.0122920.e015){ref-type="disp-formula"}), a scaling of the AIF (*C* ~*P*~) would lead to an inversely scaled *V* ~*T*~. A more than 2 fold larger *V* ~*T*~ was observed in Lopresti et al. \[[@pone.0122920.ref014]\] when uncorrected carotid ROI TAC was used as the AIF. On the other hand, our estimated *V* ~*T*~ using IDAIF was in line with literature reported values. In addition, our estimated *DVR* ~*kinetic*~ using a kinetic modeling approach with IDAIF for individual regions without any reference region was in good agreement with the reference region based *DVR* ~*REF*~. These two facts indicated our IDAIF was an accurate representation of real plasma arterial input to the brain. We are currently pursuing a full validation study by comparing directly IDAIF based amyloid imaging quantification against arterial sampling based quantification. Nevertheless, the results presented in this study provided evidence that the IDAIF technique was a viable approach for amyloid imaging quantification without reference region.

It was observed that the variability of regional *V* ~*T*~ in the PiB- group (14.8%) was higher than the *DVR* measurements (4.3% for *DVR* ~*REF*~) ([Table 2](#pone.0122920.t002){ref-type="table"} and [Fig 4](#pone.0122920.g004){ref-type="fig"}) as observed previously \[[@pone.0122920.ref024]\]. Further investigation into this observation revealed a strong correlation between cerebellar cortex *V* ~*T*~ and regional *K* ~*1*~ */k* ~*2*~ in the PiB- group (r = 0.969 for mean cortical ROI, r = 0.891 for caudate), suggesting the variation was largely due to factors that did not vary spatially. Therefore the most likely source of variability in regional *V* ~*T*~ was either noise in the AIF, or variation in global perfusion, but not regional tracer delivery and transport. The fact that there is a similar level of variability in cerebellar cortex *V* ~*T*~ in our study and previous studies \[[@pone.0122920.ref014],[@pone.0122920.ref015],[@pone.0122920.ref024]\] indicated that the noise level in the IDAIF was comparable to arterial sampling based AIF. This variability would be reduced by using a reference region based approach or full kinetic modeling since the effect of *K* ~*1*~ and *k* ~*2*~ could be removed from such analyses. There was a similar level of variability in regional *DVR* between the two methods (*DVR* ~*REF*~ and *DVR* ~*kinetic*~).

It should be pointed out that our proposed method used a population based parent compound ratio for metabolites correction similar to what has been done by Lopresti et al. \[[@pone.0122920.ref014]\] in their evaluation of image-derived AIF from carotid artery. One limitation of this approach is the potential bias caused by individual variability of tracer metabolism. This limitation can be avoided by performing metabolites analysis with venous samples, given the sparse sampling typically performed for this type of analysis \[[@pone.0122920.ref014],[@pone.0122920.ref015]\]. It should also be kept in mind that parent compound ratio measurements can be noisy and may not be reliable on an individual basis.

As mentioned earlier, while using cerebellar cortex as the reference was the accepted standard for amyloid imaging quantification \[[@pone.0122920.ref014],[@pone.0122920.ref015]\], in certain population such as familial AD \[[@pone.0122920.ref030]--[@pone.0122920.ref032]\] and prion disease \[[@pone.0122920.ref028],[@pone.0122920.ref029]\], amyloid plaque has been found in the cerebellum. Because of this, Edison et al. (2012) specifically validated pons as an alternative reference. Based on results from our study, it could be seen that brain stem as defined in FreeSurfer which included the pontine region could also serve as a reference region where no detectable difference in PiB uptake between the PiB- and the PiB+ group. This supported the use of brain stem as the reference region in our previous \[[@pone.0122920.ref004],[@pone.0122920.ref053]\] and ongoing studies of the DIAN cohort. Even within the group examined in this study which did not have familial AD nor prion disease, the assumption of comparable tracer delivery and nonspecific binding between the reference region and target region did not always hold. For example, when mean cortical *K* ~*1*~ */k* ~*2*~ was compared to cerebellum *V* ~*T*~, there were three cases that had a difference greater than 15%. In the case with the largest discrepancy (22%), it led to an 18% difference between *DVR* estimated with a reference region (*DVR* ~*REF*~) and a kinetic modeling approach (*DVR* ~*kinetic*~) independent of reference region. Given the uncertainty in reference region validity and the effectiveness of estimating regional *DVR* using IDAIF with kinetic modeling, quantification of amyloid PET imaging using the proposed IDAIF technique would be beneficial not only in the population with suspected cerebellum uptake, but also in sporadic AD population as well.

Conclusion {#sec012}
==========

An image-based method to derive arterial input function was developed and evaluated in the context of amyloid PET imaging quantification. Excellent agreement in distribution volume measurements was observed between the IDAIF technique and the reference region based method. This demonstrates the IDAIF technique was a viable approach to quantify amyloid imaging data to eliminate the need of arterial sampling or a reference region. Further investigation is ongoing to apply this technique in population with suspected specific uptake of PiB in proposed reference tissue and to provide full validation with arterial sampling data.
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